Dual anti-platelet therapy after coronary artery bypass grafting: Is there any benefit? A systematic review and meta-analysis

Salil V. Deo, Shannon M Dunlay, Ishan K. Shah, Salah E. Altarabsheh, Patricia J. Erwin, Barry A. Boilson, Soon J. Park, Lyle D. Joyce

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Background Anti-platelet therapy is an important component of medical therapy post coronary artery bypass grafting (CABG). While aspirin administration is a Class I indication after CABG, the benefit of concomitant clopidogrel is a controversial issue. Methods We searched OVID Medline, Cochrane, Scopus, and EMBASE for randomized control trials and observational studies comparing aspirin ± placebo to aspirin + clopidogrel after CABG. Results Eleven articles (five randomized control trials and six observational studies) including 25,728 patients met inclusion criteria. Early saphenous vein graft occlusion was reduced with the use of dual anti-platelet therapy (risk ratio (RR) = 0.59, 95% CI 0.43-0.82, p = 0.02). In-hospital or 30-day mortality was lower with aspirin + clopidogrel (0.8%) compared to aspirin alone (1.9%) (p < 0.0001), while risk of angina or perioperative myocardial infarction was comparable (RR = 0.60, 95% CI 0.31-1.14, p = 0.12). Patients treated with aspirin + clopidogrel demonstrated a trend towards a higher incidence of major bleeding episodes as compared to patients treated with aspirin alone (RR = 1.17, 95% CI 1.00-1.37, p = 0.05). In a pooled analysis of studies involving off-pump CABG compared to aspirin alone, dual anti-platelet therapy reduced the risk of perioperative myocardial infarction and saphenous graft occlusion by 68% (47% to 71%) and 55% (2% to 79%) respectively. Conclusion Dual anti-platelet therapy after CABG improved early saphenous vein graft patency, but may increase the risk of bleeding. The use of dual anti-platelet therapy appears to be most beneficial in patients undergoing off-pump CABG. Prospective randomized studies are necessary to determine whether this beneficial effect of dual therapy is also achieved in patients undergoing on pump CABG.

Original languageEnglish (US)
Pages (from-to)109-116
Number of pages8
JournalJournal of Cardiac Surgery
Volume28
Issue number2
DOIs
StatePublished - Mar 2013

Fingerprint

clopidogrel
Coronary Artery Bypass
Aspirin
Meta-Analysis
Blood Platelets
Off-Pump Coronary Artery Bypass
Odds Ratio
Saphenous Vein
Therapeutics
Transplants
Observational Studies
Myocardial Infarction
Hemorrhage
Placebos
Prospective Studies
Mortality
Incidence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Dual anti-platelet therapy after coronary artery bypass grafting : Is there any benefit? A systematic review and meta-analysis. / Deo, Salil V.; Dunlay, Shannon M; Shah, Ishan K.; Altarabsheh, Salah E.; Erwin, Patricia J.; Boilson, Barry A.; Park, Soon J.; Joyce, Lyle D.

In: Journal of Cardiac Surgery, Vol. 28, No. 2, 03.2013, p. 109-116.

Research output: Contribution to journalArticle

Deo, Salil V. ; Dunlay, Shannon M ; Shah, Ishan K. ; Altarabsheh, Salah E. ; Erwin, Patricia J. ; Boilson, Barry A. ; Park, Soon J. ; Joyce, Lyle D. / Dual anti-platelet therapy after coronary artery bypass grafting : Is there any benefit? A systematic review and meta-analysis. In: Journal of Cardiac Surgery. 2013 ; Vol. 28, No. 2. pp. 109-116.
@article{e48cf2b023664771a2b7116a7cffdef4,
title = "Dual anti-platelet therapy after coronary artery bypass grafting: Is there any benefit? A systematic review and meta-analysis",
abstract = "Background Anti-platelet therapy is an important component of medical therapy post coronary artery bypass grafting (CABG). While aspirin administration is a Class I indication after CABG, the benefit of concomitant clopidogrel is a controversial issue. Methods We searched OVID Medline, Cochrane, Scopus, and EMBASE for randomized control trials and observational studies comparing aspirin {\^A}± placebo to aspirin + clopidogrel after CABG. Results Eleven articles (five randomized control trials and six observational studies) including 25,728 patients met inclusion criteria. Early saphenous vein graft occlusion was reduced with the use of dual anti-platelet therapy (risk ratio (RR) = 0.59, 95{\%} CI 0.43-0.82, p = 0.02). In-hospital or 30-day mortality was lower with aspirin + clopidogrel (0.8{\%}) compared to aspirin alone (1.9{\%}) (p < 0.0001), while risk of angina or perioperative myocardial infarction was comparable (RR = 0.60, 95{\%} CI 0.31-1.14, p = 0.12). Patients treated with aspirin + clopidogrel demonstrated a trend towards a higher incidence of major bleeding episodes as compared to patients treated with aspirin alone (RR = 1.17, 95{\%} CI 1.00-1.37, p = 0.05). In a pooled analysis of studies involving off-pump CABG compared to aspirin alone, dual anti-platelet therapy reduced the risk of perioperative myocardial infarction and saphenous graft occlusion by 68{\%} (47{\%} to 71{\%}) and 55{\%} (2{\%} to 79{\%}) respectively. Conclusion Dual anti-platelet therapy after CABG improved early saphenous vein graft patency, but may increase the risk of bleeding. The use of dual anti-platelet therapy appears to be most beneficial in patients undergoing off-pump CABG. Prospective randomized studies are necessary to determine whether this beneficial effect of dual therapy is also achieved in patients undergoing on pump CABG.",
author = "Deo, {Salil V.} and Dunlay, {Shannon M} and Shah, {Ishan K.} and Altarabsheh, {Salah E.} and Erwin, {Patricia J.} and Boilson, {Barry A.} and Park, {Soon J.} and Joyce, {Lyle D.}",
year = "2013",
month = "3",
doi = "10.1111/jocs.12074",
language = "English (US)",
volume = "28",
pages = "109--116",
journal = "Journal of Cardiac Surgery",
issn = "0886-0440",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Dual anti-platelet therapy after coronary artery bypass grafting

T2 - Is there any benefit? A systematic review and meta-analysis

AU - Deo, Salil V.

AU - Dunlay, Shannon M

AU - Shah, Ishan K.

AU - Altarabsheh, Salah E.

AU - Erwin, Patricia J.

AU - Boilson, Barry A.

AU - Park, Soon J.

AU - Joyce, Lyle D.

PY - 2013/3

Y1 - 2013/3

N2 - Background Anti-platelet therapy is an important component of medical therapy post coronary artery bypass grafting (CABG). While aspirin administration is a Class I indication after CABG, the benefit of concomitant clopidogrel is a controversial issue. Methods We searched OVID Medline, Cochrane, Scopus, and EMBASE for randomized control trials and observational studies comparing aspirin ± placebo to aspirin + clopidogrel after CABG. Results Eleven articles (five randomized control trials and six observational studies) including 25,728 patients met inclusion criteria. Early saphenous vein graft occlusion was reduced with the use of dual anti-platelet therapy (risk ratio (RR) = 0.59, 95% CI 0.43-0.82, p = 0.02). In-hospital or 30-day mortality was lower with aspirin + clopidogrel (0.8%) compared to aspirin alone (1.9%) (p < 0.0001), while risk of angina or perioperative myocardial infarction was comparable (RR = 0.60, 95% CI 0.31-1.14, p = 0.12). Patients treated with aspirin + clopidogrel demonstrated a trend towards a higher incidence of major bleeding episodes as compared to patients treated with aspirin alone (RR = 1.17, 95% CI 1.00-1.37, p = 0.05). In a pooled analysis of studies involving off-pump CABG compared to aspirin alone, dual anti-platelet therapy reduced the risk of perioperative myocardial infarction and saphenous graft occlusion by 68% (47% to 71%) and 55% (2% to 79%) respectively. Conclusion Dual anti-platelet therapy after CABG improved early saphenous vein graft patency, but may increase the risk of bleeding. The use of dual anti-platelet therapy appears to be most beneficial in patients undergoing off-pump CABG. Prospective randomized studies are necessary to determine whether this beneficial effect of dual therapy is also achieved in patients undergoing on pump CABG.

AB - Background Anti-platelet therapy is an important component of medical therapy post coronary artery bypass grafting (CABG). While aspirin administration is a Class I indication after CABG, the benefit of concomitant clopidogrel is a controversial issue. Methods We searched OVID Medline, Cochrane, Scopus, and EMBASE for randomized control trials and observational studies comparing aspirin ± placebo to aspirin + clopidogrel after CABG. Results Eleven articles (five randomized control trials and six observational studies) including 25,728 patients met inclusion criteria. Early saphenous vein graft occlusion was reduced with the use of dual anti-platelet therapy (risk ratio (RR) = 0.59, 95% CI 0.43-0.82, p = 0.02). In-hospital or 30-day mortality was lower with aspirin + clopidogrel (0.8%) compared to aspirin alone (1.9%) (p < 0.0001), while risk of angina or perioperative myocardial infarction was comparable (RR = 0.60, 95% CI 0.31-1.14, p = 0.12). Patients treated with aspirin + clopidogrel demonstrated a trend towards a higher incidence of major bleeding episodes as compared to patients treated with aspirin alone (RR = 1.17, 95% CI 1.00-1.37, p = 0.05). In a pooled analysis of studies involving off-pump CABG compared to aspirin alone, dual anti-platelet therapy reduced the risk of perioperative myocardial infarction and saphenous graft occlusion by 68% (47% to 71%) and 55% (2% to 79%) respectively. Conclusion Dual anti-platelet therapy after CABG improved early saphenous vein graft patency, but may increase the risk of bleeding. The use of dual anti-platelet therapy appears to be most beneficial in patients undergoing off-pump CABG. Prospective randomized studies are necessary to determine whether this beneficial effect of dual therapy is also achieved in patients undergoing on pump CABG.

UR - http://www.scopus.com/inward/record.url?scp=84875124713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875124713&partnerID=8YFLogxK

U2 - 10.1111/jocs.12074

DO - 10.1111/jocs.12074

M3 - Article

C2 - 23488578

AN - SCOPUS:84875124713

VL - 28

SP - 109

EP - 116

JO - Journal of Cardiac Surgery

JF - Journal of Cardiac Surgery

SN - 0886-0440

IS - 2

ER -